Mbrace Therapeutics is a company focused on developing antibody-drug conjugates (ADCs) for cancer treatment. They work on discovering novel ADC targets for cancers that are not yet treatable with existing therapies or have resistance mechanisms to existing drugs.

MBrace Therapeutics

Mbrace Therapeutics

MBrace Therapeutics is a privately-held biopharmaceutical company devoted to improving the lives of cancer patients through the development of antibody-drug conjugates (ADCs) against novel oncology targets. MBrace is supported by a world-class investor syndicate, including TPG, Avidity Partners, Cowen Healthcare Investments, Venrock and Alta Partners.

We are excited to share that Reena R Desai has joined MBrace as #ChiefLegalOfficer and Corporate Secretary. Reena brings almost 25 years of experience from various #biotech and #pharmaceutical companies. She will be responsible for shaping the company’s #legal strategy at MBrace. Welcome, Reena!

The Wall Street Journal recently featured MBrace along with other leading innovators in the #ADC field, highlighting our SPARTA platform’s ability to search for potential novel targets that allow #ADCs to zero in on #tumors, exit the bloodstream and enter #cancer cells:
https://bit.ly/3y3KkFF

#ICYMI: STAT recently covered the appointment of MBrace chief scientific officer Steve Alley, Ph.D., and offered a glimpse into his unique interests and hobbies outside of the lab, including hiking and bird watching. Read more about Steve’s favorite hiking and bird watching experiences, including a chance encounter with a Magellanic penguin, here: https://lnkd.in/ei53g6J5

It’s an exciting time in the field of #oncology and #ADC innovation. It was impactful for our team to be a part of a community of dedicated and passionate individuals at #ASCO24, and we look forward to continuing to explore MBRC-101's therapeutic potential to meaningfully impact outcomes for individuals with difficult-to-treat cancers.

We look forward to presenting a trial in progress update for the Phase 1/1b study of MBRC-101 at #ASCO24. This clinical program demonstrates our commitment to both break new ground in #ADC innovation and bridge gaps within current #cancer treatment paradigms. 

Learn more: https://bit.ly/4bD5Fos

Please join us in welcoming the newest addition to our #leadership team, Steve Alley, Ph.D., joining as chief scientific officer!

With over 20 years of experience in discovery and #drugdevelopment, from leading clinical development programs and overseeing a robust commercial portfolio of #antibodydrugconjugates, Dr. Alley will play a pivotal role in driving our #research and development efforts forward. 

#oncologynews #biotech #stem #oncology

https://lnkd.in/e3wqf7g8

MBRA

COM:MBRACETRX

Mbrace Therapeutics

name

homepage url

country

linkedin url

employee count

sector

industry

Description

investor of

Metrics